[The role of cAMP phosphodiesterase inhibitors in the pharmacotherapy of the hypoxic syndrome].

The authors studied the pharmacotherapeutic activity of drugs belonging to various pharmacological groups which are inhibitors of cAMP phosphodiesterase in the hypoxic syndrome. The increase in the level of the secondary intermediate of the adenylate cyclase path in transmission of the intracellular signal from the outer surface of the cell to the nucleus, the hypoxia protector cAMP, under the effect of the drugs under study favorably influenced survival and the course of hypoxic hypoxia in overheating. A combination of quercetin bioflavonoid with acetylsalicylic acid demonstrated stronger antihypoxic and thermoprotector properties. The results were less marked with the use of the calcium channel blocker cinnarizine and an agent of the xanthine pentoxyfelline group. The possible mechanisms of the antihypoxic activity of the drugs under study are discussed.